Immune activation pathways in mitomycin C-treated donor peripheral blood mononuclear cells

Immune activation pathways in mitomycin C-treated donor peripheral blood mononuclear cells (PBMCs) refer to the complex immunological processes that occur when donor cells are chemically inactivated for use in diagnostic or therapeutic applications. Mitomycin C is a potent DNA-crosslinking agent used to arrest the cell cycle of 'stimulator' cells in Mixed Lymphocyte Reactions (MLR) or cellular vaccines, ensuring they cannot divide while remaining immunologically functional. These pathways involve the presentation of antigens through Major Histocompatibility Complex (MHC) molecules and the engagement of costimulatory receptors (such as CD80/86) on the treated cells with T-cell receptors on responder cells (PubMed: 10936305). While the treatment effectively halts DNA synthesis, the cells continue to synthesize RNA and proteins, allowing them to secrete cytokines and maintain the surface architecture necessary for immune recognition. This process is critical in transplantation medicine for assessing histocompatibility and in oncology for developing cell-based immunotherapies. Because this entry describes a multi-component biological state and experimental condition rather than a single protein or receptor, it is classified as a pathway or cellular process rather than a discrete therapeutic target.

Other names

Mitomycin C-treated PBMC activationMMC-treated donor cell pathwaysInactivated stimulator cell pathwaysMixed Lymphocyte Reaction (MLR) stimulator pathways

Mitomycin C (MMC) acts as a bioreductive alkylating agent that forms covalent DNA cross-links, primarily at deoxyguanosine residues. This inhibits DNA replication and cell proliferation while maintaining the metabolic activity and surface protein expression of the peripheral blood mononuclear cells (PBMCs). In this state, the cells can still present antigens via MHC molecules and provide costimulatory signals to responder T-cells (PubChem CID 5746; PubMed: 2528657).